Cynapsus preclinical data

A hamster irritation study showed that thrice-daily sublingual APL-130277 for 28 days led to no irritation as determined macroscopically (by clinician observation of the oral cavity) or microscopically. Cynapsus said the study is required by FDA for registration. APL-130277 is a sublingual thin film strip formulation of apomorphine, a small molecule dopamine receptor agonist. Next quarter, the company plans to complete the pilot CTH-105 trial of APL-130277 in apomorphine-naïve PD patients and the CTH-200 bridging study. A safety trial in apomorphine-naïve PD patients is slated to be completed by year end 2015. ...